|
July 27, 2021
|
Caribou Biosciences Announces Closing of Upsized Initial Public Offering
|
|
|
July 22, 2021
|
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
|
|
|
July 12, 2021
|
Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
|
|
|
June 22, 2021
|
Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors
|
|
|
May 17, 2021
|
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
|
|
|
May 5, 2021
|
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
|
|
|
March 8, 2021
|
Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March
|
|
|
March 3, 2021
|
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
|
|
|
February 10, 2021
|
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
|
|
|
February 9, 2021
|
Caribou Biosciences Appoints Jason O’Byrne as Chief Financial Officer
|
|
